AI filing briefs · archive

8-K filings in December 2025, explained

619 material Form 8-K filings that 507 companies we cover made with the SEC in December 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

4 of 619 briefs match

newest first · times in ET
AGNTAGNT, Inc. Dec 30, 1:22 PM ET

eXp World ends annual bonus program for three executives, raises their base salaries

Neutral leadership Written later 5.02

eXp World Holdings disclosed that its Board approved a change to the cash pay of three executive officers: Leo Pareja, Wendy Forsythe, and James Bramble. Starting January 1, 2026, these officers will no longer take part in the discretionary annual cash bonus program, and their base salaries will rise by the amount of their maximum annual bonus target. The filing gives no dollar figures, so shareholders cannot yet judge the effect on total pay costs.

  • Board approved the change on December 23, 2025; it takes effect January 1, 2026.
  • Covered officers: Leo Pareja (CEO, eXp Realty), Wendy Forsythe (Chief Marketing Officer), and James Bramble (Chief Legal Counsel and Corporate Secretary).
  • Each officer's base salary rises by an amount equal to his or her maximum annual bonus target, and the officers exit the discretionary annual bonus program.
  • The filing does not state the dollar amounts of the salary increases or the bonus targets.
Read the filing on SEC.gov ↗
FLSFLOWSERVE CORP Dec 30, 9:00 AM ET

Flowserve director Kenneth Siegel will not stand for re-election in 2026

Neutral leadership Written later 5.02

Flowserve director Kenneth I. Siegel told the board on December 29, 2025 that he will not stand for re-election at the company's 2026 annual meeting. He will remain a director until that meeting, and the filing states his decision was not due to any disagreement with management or the board.

  • Kenneth I. Siegel informed the board on December 29, 2025 of his decision
  • He will continue to serve as a director until the 2026 annual meeting of shareholders
  • The filing states the decision was not the result of any disagreement with management or the board
Read the filing on SEC.gov ↗
CACICACI INTERNATIONAL INC /DE/ Dec 30, 8:33 AM ET

CACI Appoints Michael Gilday and David Keffer to Board; Jews Resigns Dec. 31

Neutral leadership Written later 5.02

CACI International named two new independent directors, retired Adm. Michael Gilday and David Keffer, effective January 1, 2026. They fill vacancies left by the resignation of William L. Jews, effective December 31, 2025, and the death of Michael A. Daniels in July 2025.

  • Michael Gilday and David Keffer appointed to the Board effective January 1, 2026, by Board action on December 29, 2025.
  • William L. Jews, Audit Committee chair, resigned effective December 31, 2025; the filing says the resignation was not due to a disagreement with the company.
  • Both new directors are independent under NYSE requirements and will serve initial terms ending at the next annual shareholder meeting.
  • Keffer previously served as CFO of Northrop Grumman before retiring in 2024; Gilday most recently retired as Chief of Naval Operations.
Read the filing on SEC.gov ↗
NEONEOGENOMICS INC Dec 30, 7:07 AM ET

NeoGenomics names Jack Kenny to board, filling seat left by Alison Hannah

Neutral leadership Written later 5.02

NeoGenomics said director Alison L. Hannah, MD, resigned effective December 31, 2025, and the Board appointed John P. "Jack" Kenny to fill the vacancy effective January 1, 2026. Kenny will serve until the 2026 annual meeting and will receive independent director compensation under the company's existing program. The change affects board composition but the filing does not report any financial figures.

  • Dr. Alison L. Hannah's resignation as director is effective December 31, 2025; the Board accepted it on December 23, 2025.
  • Jack Kenny was appointed to the Board effective January 1, 2026, to fill the vacancy.
  • Kenny previously served as President, Chief Executive Officer and Board Director of Meridian Bioscience, per the press release (Exhibit 99.1, dated December 29, 2025).
  • Kenny will serve until the 2026 annual meeting, and the filing reports no related-party transactions requiring disclosure under Item 404(a).
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.